FDA has requested additional clinical data from Clovis Oncology Inc., for the agency’s efficacy analysis of the 500mg and 625mg BID dose patient groups for rociletinib. Clovis said it would provide the information in a major amendment to the FDA.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
